⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Orion Oyj A (ORNAV)

Helsinki
Currency in EUR
44.55
+0.15(+0.34%)
Real-time Data
ORNAV Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
Fair Value
Day's Range
44.0544.55
52 wk Range
32.5049.85
Key Statistics
Edit
Prev. Close
44.4
Open
44.4
Day's Range
44.05-44.55
52 wk Range
32.5-49.85
Volume
1.35K
Average Volume (3m)
6.28K
1-Year Change
21.98%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORNAV Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
49.17
Upside
+10.37%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility
Show more

Orion Oyj A Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Employees
3632
Market
Finland

Compare ORNAV to Peers and Sector

Metrics to compare
ORNAV
Peers
Sector
Relationship
P/E Ratio
18.9x19.1x−0.7x
PEG Ratio
0.210.030.00
Price/Book
6.8x2.2x2.6x
Price / LTM Sales
4.4x2.1x3.2x
Upside (Analyst Target)
-26.1%46.4%
Fair Value Upside
Unlock12.1%6.9%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.36
Dividend Yield
3.65%
Industry Median 4.21%
Annualised payout
1.6200
Paid unevenly
5-Years Growth
-
Growth Streak

FAQ

What Is the Orion Oyj A (ORNAV) Stock Price Today?

The Orion Oyj A stock price today is 44.55.

What Stock Exchange Does Orion Oyj A Trade On?

Orion Oyj A is listed and trades on the Helsinki stock exchange.

What Is the Stock Symbol for Orion Oyj A?

The stock symbol for Orion Oyj A is "ORNAV."

Does Orion Oyj A Pay Dividends? What’s The Current Dividend Yield?

The Orion Oyj A dividend yield is 3.65%.

What Is the Orion Oyj A Market Cap?

As of today, Orion Oyj A market cap is 6.23B.

What is Orion Oyj A Earnings Per Share?

The Orion Oyj A EPS is 2.36.

What Is the Next Orion Oyj A Earnings Date?

Orion Oyj A will release its next earnings report on 24 Feb 2025.

From a Technical Analysis Perspective, Is ORNAV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.